Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-15

Clinical Trial Update: Aflibercept in Polypoidal Choroidal Vasculopathy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating aflibercept for neovascular macular degeneration has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aflibercept (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Neovascular Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2019-01-15